BI 836880

DRUG8 trials

Conditions

Advanced TumorsAnal Canal Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC)Metastatic Solid TumorsNeoplasm MetastasisNeoplasmsNon-squamous, Non-Small-Cell Lung CancerWet Macular Degeneration

Phase 1

Dose Finding Study of BI 836880 in Patients With Solid Tumors

CompletedNCT02674152

Boehringer IngelheimNeoplasms

Start: 2016-01-05End: 2020-11-04Updated: 2025-10-01

Weekly BI 836880 in Patients With Advanced Solid Tumors

CompletedNCT02689505

Boehringer IngelheimNeoplasms

Start: 2016-04-04End: 2019-07-31Updated: 2025-10-01

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

CompletedNCT03468426

Boehringer IngelheimNeoplasms, Non-squamous, Non-Small-Cell Lung Cancer

Start: 2018-07-05End: 2024-09-12Updated: 2025-11-07

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

CompletedNCT03861234

Boehringer IngelheimWet Macular Degeneration

Start: 2019-06-27End: 2023-11-01Updated: 2024-11-20

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

CompletedNCT03972150

Boehringer IngelheimNeoplasms

Start: 2019-06-12End: 2022-03-28Updated: 2025-10-06

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Active, not recruitingNCT05249426

Boehringer IngelheimHead and Neck Squamous Cell Carcinoma (HNSCC)

Start: 2022-04-12End: 2026-07-31Updated: 2026-01-21

Phase 2

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

CompletedNCT03697304

Boehringer IngelheimAdvanced Tumors, Metastatic Solid Tumors, Neoplasm Metastasis

Start: 2019-03-19End: 2024-12-03Updated: 2026-01-27

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

WithdrawnNCT04499352

Boehringer IngelheimAnal Canal Squamous Cell Carcinoma

Start: 2020-09-14End: 2020-10-19Updated: 2021-11-15

Journal of Clinical Oncology2025-05-28

Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors

JCO oncology advances.2025-01-012 citations

Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor

Journal of Translational Medicine2024-10-142 citations

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Cancer Immunology Immunotherapy2024-03-303 citations

Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.

2023-05-045 citations

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

ESMO Open2022-09-1213 citations

Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2022-01-193 citations

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC).

Journal of Clinical Oncology2022-01-19

Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.

Journal of Clinical Oncology2021-05-204 citations

Platform trial of ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients (pts) with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.

Journal of Clinical Oncology2021-05-202 citations

Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.

Journal of Clinical Oncology2021-01-202 citations

Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.

Journal of Clinical Oncology2020-05-2013 citations

Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2020-05-203 citations

First-in-human phase I trial of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, given every 3 weeks (q3w) in patients (pts) with advanced/metastatic solid tumors.

Journal of Clinical Oncology2018-05-205 citations

A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.

Journal of Clinical Oncology2018-05-204 citations

PK/PD properties of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, in patients (pts) with advanced/metastatic solid tumors.

Journal of Clinical Oncology2018-05-201 citations

BI 836880

Sponsors

Conditions

Phase 1

Phase 2

Related Papers